Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK

被引:227
作者
Patel, Girijesh Kumar [1 ]
Khan, Mohammad Aslam [1 ]
Bhardwaj, Arun [1 ]
Srivastava, Sanjeev K. [1 ]
Zubair, Haseeb [1 ]
Patton, Mary C. [1 ]
Singh, Seema [1 ,2 ]
Khushman, Moh'd [3 ]
Singh, Ajay P. [1 ,2 ]
机构
[1] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36608 USA
[2] Univ S Alabama, Dept Biochem & Mol Biol, Coll Med, Mobile, AL 36608 USA
[3] Univ S Alabama, Mitchell Canc Inst, Dept Interdisciplinary Clin Oncol, Mobile, AL USA
关键词
chemoresistance; exosomes; pancreatic cancer; ROS; microRNA; ACQUIRED-RESISTANCE; EXPRESSION; APOPTOSIS; KINASE; SURVIVAL; 5-FLUOROURACIL; ACTIVATION; MECHANISMS; INHIBITION; SECRETION;
D O I
10.1038/bjc.2017.18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chemoresistance is a significant clinical problem in pancreatic cancer (PC) and underlying molecular mechanisms still remain to be completely understood. Here we report a novel exosome-mediated mechanism of drug-induced acquired chemoresistance in PC cells. Methods: Differential ultracentrifugation was performed to isolate extracellular vesicles (EVs) based on their size from vehicle-or gemcitabine-treated PC cells. Extracellular vesicles size and subtypes were determined by dynamic light scattering and marker profiling, respectively. Gene expression was examined by qRT-PCR and/or immunoblot analyses, and direct targeting of DCK by miR-155 was confirmed by dual-luciferase 30-UTR reporter assay. Flow cytometry was performed to examine the apoptosis indices and reactive oxygen species (ROS) levels in PC cells using specific dyes. Cell viability was determined using the WST-1 assay. Results: Conditioned media (CM) from gemcitabine-treated PC cells (Gem-CM) provided significant chemoprotection to subsequent gemcitabine toxicity and most of the chemoresistance conferred by Gem-CM resulted from its EVs fraction. Sub-fractionation grouped EVs into distinct subtypes based on size distribution and marker profiles, and exosome (Gem-Exo) was the only sub-fraction that imparted chemoresistance. Gene expression analyses demonstrated upregulation of SOD2 and CAT (ROS-detoxifying genes), and downregulation of DCK (gemcitabine-metabolising gene) in Gem-Exo-treated cells. SOD/CAT upregulation resulted, at least in part, from exosome-mediated transfer of their transcripts and they suppressed basal and gemcitabine-induced ROS production, and partly promoted chemoresistance. DCK downregulation occurred through exosome-delivered miR-155 and either the functional suppression of miR-155 or restoration of DCK led to marked abrogation of Gem-Exo-mediated chemoresistance. Conclusions: Together, these findings establish a novel role of exosomes in mediating the acquired chemoresistance of PC.
引用
收藏
页码:609 / 619
页数:11
相关论文
共 49 条
[21]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]
[22]  
Khan MA, 2015, ONCOTARGET, V6, P39140, DOI 10.18632/oncotarget.3784
[23]   Gemcitabine resistance in pancreatic cancer: Picking the key players [J].
Kim, Michael P. ;
Gallick, Gary E. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1284-1285
[24]   Smarter drugs emerging in pancreatic cancer therapy [J].
Kleger, A. ;
Perkhofer, L. ;
Seufferlein, T. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1260-1270
[25]   Reactive oxygen species in cancer [J].
Liou, Geou-Yarh ;
Storz, Peter .
FREE RADICAL RESEARCH, 2010, 44 (05) :479-496
[26]   Glypican-1 identifies cancer exosomes and detects early pancreatic cancer [J].
Melo, Sonia A. ;
Luecke, Linda B. ;
Kahlert, Christoph ;
Fernandez, Agustin F. ;
Gammon, Seth T. ;
Kaye, Judith ;
LeBleu, Valerie S. ;
Mittendorf, Elizabeth A. ;
Weitz, Juergen ;
Rahbari, Nuh ;
Reissfelder, Christoph ;
Pilarsky, Christian ;
Fraga, Mario F. ;
Piwnica-Worms, David ;
Kalluri, Raghu .
NATURE, 2015, 523 (7559) :177-U82
[27]   Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].
Moore, Malcolm J. ;
Goldstein, David ;
Hamm, John ;
Figer, Arie ;
Hecht, Joel R. ;
Gallinger, Steven ;
Au, Heather J. ;
Murawa, Pawel ;
Walde, David ;
Wolff, Robert A. ;
Campos, Daniel ;
Lim, Robert ;
Ding, Keyue ;
Clark, Gary ;
Voskoglou-Nomikos, Theodora ;
Ptasynski, Mieke ;
Parulekar, Wendy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966
[28]   Acquired chemoresistance in pancreatic carcinoma cells:: induced secretion of IL-1β and NO lead to inactivation of caspases [J].
Mueerkoester, S. Sebens ;
Lust, J. ;
Arlt, A. ;
Haesler, R. ;
Witt, M. ;
Sebens, T. ;
Schreiber, S. ;
Foelsch, U. R. ;
Schaefer, H. .
ONCOGENE, 2006, 25 (28) :3973-3981
[29]   hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review [J].
Nordh, Stina ;
Ansari, Daniel ;
Andersson, Roland .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) :8482-8490
[30]  
Ohhashi S, 2008, ANTICANCER RES, V28, P2205